Medical Information Only. Always consult your healthcare provider before enrolling in any clinical trial.

NCT05902533 · ClinicalTrials.gov registry record · Phase 2

REDEL Trial: Reduced Elective Nodal Dose for Anal Cancer Toxicity Mitigation

A Phase 2 study of Anal Cancer, sponsored by University of Cincinnati.

Active
Registry status
Phase 2
Development phase
33
Enrollment target
3
Study locations

NCT05902533 is a Phase 2 study of Anal Cancer that is active but no longer recruiting, run by University of Cincinnati. The registered enrollment target is 33 participants, below the 578-participant average among 19 other Anal Cancer trials with a reported enrollment target (94% lower). The trial reports 3 study locations across 2 states.

View on ClinicalTrials.gov ↗

View your shortlist →

The verdict

NCT05902533, a Phase 2 study of Anal Cancer, is active but no longer recruiting, sponsored by University of Cincinnati.

ACTIVE NOT RECRUITING
Registry status
Phase 2
Development phase
33 participants
Enrollment target
3
Study locations

Study Summary

To determine the efficacy of reduced elective nodal radiation in anal cancer patients undergoing chemoradiation in reducing toxicity compared to standard nodal irradiation.

Conditions Studied

Anal Cancer

Interventions

  • DRUG Capecitabine
  • RADIATION Radiation (reduced elective nodal dose (30.6 Gy)
  • DRUG Mitomycin c

Study Locations (3)

Ohio

  • University of Cincinnati Medical Center - Cincinnati
  • Ohio State University Medical Center - Columbus

Vermont

  • University of Vermont - Burlington

Trial Details

FieldValue
Enrollment Target 33 participants
Start Date 2023-08-14
Est. Completion 2029-08-14
Phase Phase 2

Sponsor

University of Cincinnati

245 total trials

Interested in This Trial?

Full Details on ClinicalTrials.gov ↗

What the Registry Record Tells You About NCT05902533

The ClinicalTrials.gov registry entry for NCT05902533 describes a study currently listed as active not recruiting, categorized as Phase 2. The registered enrollment target is 33 participants, a figure that helps gauge the scale of data the investigators plan to collect, below the 578-participant average among 19 other Anal Cancer trials with a reported enrollment target (94% lower). The listed sponsor is University of Cincinnati, which has 245 total studies on file at ClinicalTrials.gov.

The record links to 1 condition, with Anal Cancer appearing as the primary indexed condition, and to 3 interventions - of which Capecitabine is the first listed.

NCT05902533 reports 3 study locations spanning 2 distinct geographic areas - top geographies include Ohio, Vermont.

Frequently Asked Questions

What is clinical trial NCT05902533 about?

NCT05902533 is a clinical study titled "REDEL Trial: Reduced Elective Nodal Dose for Anal Cancer Toxicity Mitigation". To determine the efficacy of reduced elective nodal radiation in anal cancer patients undergoing chemoradiation in reducing toxicity compared to standard nodal irradiation.

What is the current status of trial NCT05902533?

This trial is currently active not recruiting. It is a Phase 2 study. The enrollment target is 33 participants. The study started on 2023-08-14. Estimated completion is 2029-08-14.

What conditions does trial NCT05902533 study?

This clinical trial studies the following conditions: Anal Cancer.

What interventions are being tested in trial NCT05902533?

The interventions under investigation include: Capecitabine (DRUG), Radiation (reduced elective nodal dose (30.6 Gy) (RADIATION), Mitomycin c (DRUG).

Who is sponsoring clinical trial NCT05902533?

This trial is sponsored by University of Cincinnati, which has 245 total clinical trials registered on ClinicalTrials.gov.

Where is trial NCT05902533 being conducted?

This trial has 3 study locations across Ohio, Vermont. Contact the study sites directly through ClinicalTrials.gov for enrollment availability.

Learn More About Clinical Trials

Similar trials for Anal Cancer

Matched on the same primary condition, ranked to surface studies in the same phase first, then by recruiting status, no relevance scoring or editorial curation.

Explore more on PlainTrial

Anal Cancer

All registered trials for this condition

Ohio

All trials with a study site in Ohio

Recruiting now

Find trials open to new participants near you

Rankings

Top sponsors, conditions, and phases

Read our methodology - how this data is sourced, computed, and verified.

Related

Browse all → | Rankings →
Data sourced from official public datasets. See our methodology for details. Retrieved and formatted by PlainTrial Editorial

Every figure on PlainTrial is rendered directly from the ClinicalTrials.gov registry, no number is typed in by an editor. This page mirrors this trial's own ClinicalTrials.gov registry record, live from the dataset. See our editorial standards & corrections policy, the methodology behind these numbers, or report a data error.